Abstract:The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets. There is a pressing need for novel drugs, and much hope has been placed on the use of molecular genetics to help define them. However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle. Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-analysis indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk. Linkage analysis has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic aetiology with bipolar disorder. The identification of these loci together with advances in genetic technology, especially the characterisation of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin. Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia. We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant association with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT). The replication of neuregulin 1 association on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 years ago.

Common and Rare Genetic Risk Factors Converge in Protein Interaction Networks Underlying Schizophrenia

Network-wide risk convergence in gene co-expression identifies reproducible genetic hubs of schizophrenia risk

Synergistic effects of common schizophrenia risk variants

Convergent Impact of Schizophrenia Risk Genes

Protein-interaction-network-based analysis for genome-wide association analysis of schizophrenia in Han Chinese population

Comprehensive Pathway Analyses of Schizophrenia Risk Loci Point to Dysfunctional Postsynaptic Signaling

Whole-genome Sequencing of Monozygotic Twins Discordant for Schizophrenia Indicates Multiple Genetic Risk Factors for Schizophrenia.

Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia

The genetics of schizophrenia: glutamate not dopamine?

Network-Based Analysis Of Schizophrenia Genome-Wide Association Data To Detect The Joint Functional Association Signals

Systematic prioritization and integrative analysis of copy number variations in schizophrenia reveal key schizophrenia susceptibility genes

Integrating genome-wide association study with regulatory SNP annotation information identified candidate genes and pathways for schizophrenia.

Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data

Integrating Genome-Wide Association Study and Expression Quantitative Trait Locus Study Identifies Multiple Genes and Gene Sets Associated with Schizophrenia

Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia

Multiple Rare Risk Coding Variants in Postsynaptic Density-Related Genes Associated With Schizophrenia Susceptibility

Consensus molecular environment of schizophrenia risk genes in coexpression networks shifting across age and brain regions

Pathway-wide Association Study Identifies Five Shared Pathways Associated with Schizophrenia in Three Ancestral Distinct Populations

Genome-wide approaches to schizophrenia

Multifaceted genomic risk for brain function in schizophrenia.

Genetic Diversity in Schizophrenia: Developmental Implications of Ultra-Rare, Protein-Truncating Mutations